The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Official Title: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Study ID: NCT04904588
Brief Summary: This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Detailed Description:
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope National Medical Center, Duarte, California, United States
University of California San Francisco, San Francisco, California, United States
Stanford University, Stanford, California, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
University of Florida Health Shands Hospital, Gainesville, Florida, United States
University of Miami Sylvester Cancer Center, Miami, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Emory University Medical Center, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
The University of Chicago, Chicago, Illinois, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Tufts Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan Medical Center - Mott Children's Hospita, Ann Arbor, Michigan, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Thomas Jefferson University Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
TriStar BMT, Nashville, Tennessee, United States
TriStar Medical Group Children's Specialists, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
St. David's South Austin Medical Center, Austin, Texas, United States
-Baylor College of Medicine - Texas Children's Hospital and Houston Methodist, Houston, Texas, United States
Texas Transplant Institute, San Antonio, Texas, United States
University of Virginia, Charlottesville, Virginia, United States
Virginia Commonwealth University, Richmond, Virginia, United States
University of Wisconsin Hospital and Clinic, Madison, Wisconsin, United States
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Name: Steven Devine, MD
Affiliation: NMDP/Be The Match
Role: PRINCIPAL_INVESTIGATOR